Briacell Therapeutics Corp. Common Shares (BCTX) Stock Price
BCTXStock
$3.40−71.61%52W
Market Cap$29.58M
P/E—
PEG Ratio—
Div yield—
Beta1.04
BCTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-29.77%
Price vs S&P 500 (4W)-16.10%
VGM Score39.60
BCTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2025 | -$12.11 | $0.04 | +100.37%(+$12.15) | |
| Q1 2025 | -$17.60 | -$16.40 | +6.82%(+$1.20) | |
| Q4 2024 | -$19.40 | -$23.30 | -20.10%(-$3.90) | |
| Q3 2024 | -$12.00 | -$33.00 | -175.00%(-$21.00) |
BCTX Analyst Recommendations
Oct 2022
Nov 2022
Dec 2022
Jan 2023
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
BCTXBriacell Therapeutics Corp. Common Shares | — | — | D | — | — | — | — | $3.40 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Briacell Therapeutics Corp. Common Shares
BriaCell Therapeutics is a clinical-stage biotech company developing targeted cell-based immunotherapies for cancer. Lead program Bria-IMT is in end-stage clinical trials for breast cancer, while Bria-OTS offers personalized immunotherapy options for breast and prostate cancer. The company is evaluating combination therapy approaches through clinical collaborations.